Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.
Neurol Clin Pract
April 2025
Department of Neurology, New York University Langone Health.
Background And Objectives: Neurosarcoidosis poses a diagnostic and management challenge due to its rarity, phenotypic variability, and lack of randomized controlled studies to guide treatment selection. Recommendations for management based on expert opinion are useful in clinical practice and provide a framework for designing prospective studies.
Methods: In this Delphi survey study, specialists with experience in managing patients with neurosarcoidosis were invited to anonymously complete 2 surveys about key elements of evaluation, diagnosis, treatment, monitoring, and long-term management of neurosarcoidosis.
Hand eczema.
Lancet
December 2024
Center for Skin Diseases, Clinic for Dermatology and Allergy, Bonn, Germany. Electronic address:
Hand eczema is a highly prevalent skin disease and one of the most common work-related disorders. In up to two-thirds of individuals affected by hand eczema, the disease becomes chronic and results in substantial personal and occupational disability. Manifestations of chronic hand eczema vary in severity and appearance over time, and people with eczema typically experience itch, pain, and a burning sensation.
View Article and Find Full Text PDFKey Clinical Massage: Tubo-ovarian abscess (TOA) is a serious health hazard for women, causing severe sepsis. Antimicrobial treatment is effective, but one-third of patients experience unfavorable outcomes. ITP, an autoimmune condition, can lead to bruising and bleeding.
View Article and Find Full Text PDFThis article presents the experience of successfully switching therapy from omalizumab 150 mg to benralizumab 30 mg/1 ml in a patient with a combined allergic and eosinophilic phenotype in the presence of hypersensitivity to nonsteroidal anti-inflammatory drugs. The effectiveness of biological therapy was evaluated when switching from omalizumab 150 mg subcutaneously at a dose of 600 mg for 36 weeks. Therapy for the drug benralizumab 30 mg/1 ml subcutaneously the first three injections monthly, the rest a month later for 52 weeks with bronchial asthma (BA), a severe uncontrolled course with a combined allergic and eosinophilic phenotype in the presence of hypersensitivity to nonsteroidal anti-inflammatory drugs in a patient Ch.
View Article and Find Full Text PDFMonitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?
Allergol Select
March 2024
Upper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University and Ghent, University Hospital, Ghent, Belgium.
Article Synopsis
- Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory condition often treated with the anti-IL-5 antibody mepolizumab, which was approved as an additional therapy in 2021 when other treatments fail.
- Current guidelines for using mepolizumab in CRSwNP lack detailed instructions on monitoring, documentation, and discontinuation protocols.
- A literature review led to recommendations for following up on treatment, ensuring adherence to therapy schedules, and guidance on possible therapy interruptions or discontinuation for patients under the German healthcare system.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!